In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday
C's case, a third oral agent could be added, but DPP-4 and SGLT2 are unlikely to get his HbA1c below 7%
However, it is crucial to understand that rodents have a much higher density of GLP-1 receptors in thyroid C-cells compared to humans
Whether it fits your case is a judgment for the prescribing provider, informed by your surgical history and current symptoms
FOR CHOCOLATE LOVERS A full-size bag provides 16 servings of 21g plant-based protein plus functional mushrooms, giving you flexibility and convenience for your daily routine